A fixed-dose combination of two endogenous mitochondrial cofactors essential for cellular energy (ATP) production. Coenzyme Q10 (Ubiquinone) acts as an electron carrier in the mitochondrial electron transport chain and a potent antioxidant. Levo-carnitine (L-carnitine) is crucial for the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation. This combination is primarily used as a metabolic enhancer and cardioprotective supplement, addressing deficiencies and supporting energy metabolism in various clinical conditions prevalent in India, such as heart failure, statin-induced myopathy, and age-related mitochondrial decline.
Adult: One tablet/capsule of CoQ10 (50mg) + L-carnitine (500mg) once or twice daily, preferably with meals containing fats. For heart failure or statin myopathy: 1-2 tablets daily.
Note: Administer with food, preferably a meal containing fats (e.g., milk, nuts, oil) to enhance absorption, especially of CoQ10. Swallow whole with a glass of water. Do not crush or chew sustained-release formulations if applicable.
Synergistically enhances mitochondrial ATP production and provides antioxidant defense. CoQ10 participates in the mitochondrial electron transport chain (Complexes I, II, and III) as a mobile electron carrier, essential for oxidative phosphorylation. Its reduced form, ubiquinol, is a potent lipophilic antioxidant protecting cell membranes and LDL cholesterol from peroxidation. L-carnitine is an obligatory cofactor for transporting activated long-chain fatty acids (acyl-CoA) across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, enabling beta-oxidation. It also modulates the acyl-CoA/CoA ratio, reducing metabolic toxicity.
Pregnancy: Category N (Not classified by US FDA). Insufficient human data. Animal studies are not conclusive. Use only if potential benefit justifies potential risk to the fetus. Not recommended for routine use.
Driving: Generally safe. Rare reports of dizziness or restlessness. Patients should assess their individual response before operating heavy machinery.
| Warfarin and other Vitamin K Antagonists | CoQ10 has structural similarity to vitamin K. May theoretically reduce anticoagulant effect, though clinical evidence is conflicting. Monitor INR closely. | Moderate |
| Statins (Atorvastatin, Simvastatin, etc.) | Statins inhibit HMG-CoA reductase, depleting endogenous CoQ10. This combination is used to counteract statin-induced myopathy. No harmful pharmacokinetic interaction. | Minor |
| Blood Pressure Medications (Beta-blockers, CCBs) | Additive effect in improving endothelial function. No adverse interaction reported. | Minor |
| Chemotherapy (Doxorubicin, Anthracyclines) | CoQ10 may have protective effects against cardiotoxicity. Use under oncologist supervision. | Moderate |
| Thyroid Hormone (Levothyroxine) | Theoretical interference with absorption. Administer at least 4-6 hours apart. | Minor |
| Insulin, Sulfonylureas (e.g., Glimepiride) | L-carnitine may enhance insulin sensitivity and increase risk of hypoglycemia. Monitor blood glucose levels. | Moderate |